-
Mashup Score: 9EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore - 7 day(s) ago
Zach Klaassen interviews Neal Shore about the EMBARK trial’s post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 11The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore - 19 day(s) ago
Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The impact of the #EMBARK trial on treatment decisions in high-risk biochemical recurrent #ProstateCancer. Neal Shore @CURCMB joins @zklaassen_md @GACancerCenter to discuss findings and potential future research directions > https://t.co/6h9NTWLNq4 https://t.co/l18jfUIoij
-
-
Mashup Score: 9EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore - 1 month(s) ago
Zach Klaassen interviews Neal Shore about the EMBARK trial’s post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#EMBARK trial: Age-stratified analysis of enzalutamide in high-risk biochemically recurrent #ProstateCancer. Neal Shore @CURCMB and @zklaassen_md @GACancerCenter discuss this post hoc analysis by age and the importance of personalized treatment decisions > https://t.co/gziIsHQkam https://t.co/m31S47ama9
-
-
Mashup Score: 11The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore - 1 month(s) ago
Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The impact of the #EMBARK trial on treatment decisions in high-risk biochemical recurrent #ProstateCancer. Neal Shore @CURCMB joins @zklaassen_md @GACancerCenter to discuss findings and potential future research directions > https://t.co/6h9NTWLNq4 https://t.co/l18jfUIoij
-
-
Mashup Score: 5EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay - 2 month(s) ago
Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The #EMBARK Trial: Enzalutamide monotherapy & combination therapy for high-risk #ProstateCancer. @dr_coops is joined by experts in the field to discuss the findings from this landmark study > https://t.co/8elnftzfD1 @SFreedlandMD @DrRanaMcKay https://t.co/SIPIyKFxVr
-
-
Mashup Score: 11EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore - 2 month(s) ago
Zach Klaassen interviews Neal Shore about the EMBARK trial’s post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#EMBARK trial: Age-stratified analysis of enzalutamide in high-risk biochemically recurrent #ProstateCancer. Neal Shore @CURCMB and @zklaassen_md @GACancerCenter discuss this post hoc analysis by age and the importance of personalized treatment decisions > https://t.co/gziIsHQkam https://t.co/m31S47ama9
-
-
Mashup Score: 11The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore - 3 month(s) ago
Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The impact of the #EMBARK trial on treatment decisions in high-risk biochemical recurrent #ProstateCancer. Neal Shore @CURCMB joins @zklaassen_md @GACancerCenter to discuss findings and potential future research directions > https://t.co/6h9NTWLNq4 https://t.co/l18jfUIoij
-
-
Mashup Score: 5EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay - 3 month(s) ago
Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The #EMBARK Trial: Enzalutamide monotherapy & combination therapy for high-risk #ProstateCancer. @dr_coops is joined by experts in the field to discuss the findings from this landmark study > https://t.co/8elnftzfD1 @SFreedlandMD @DrRanaMcKay https://t.co/SIPIyKFxVr
-
-
Mashup Score: 11EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore - 3 month(s) ago
Zach Klaassen interviews Neal Shore about the EMBARK trial’s post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#EMBARK trial: Age-stratified analysis of enzalutamide in high-risk biochemically recurrent #ProstateCancer. Neal Shore @CURCMB and @zklaassen_md @GACancerCenter discuss this post hoc analysis by age and the importance of personalized treatment decisions > https://t.co/gziIsHQkam https://t.co/m31S47ama9
-
-
Mashup Score: 11The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore - 3 month(s) ago
Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The impact of the #EMBARK trial on treatment decisions in high-risk biochemical recurrent #ProstateCancer. Neal Shore @CURCMB joins @zklaassen_md @GACancerCenter to discuss findings and potential future research directions > https://t.co/6h9NTWLNq4 https://t.co/l18jfUIoij
-
#EMBARK trial: Age-stratified analysis of enzalutamide in high-risk biochemically recurrent #ProstateCancer. Neal Shore @CURCMB and @zklaassen_md @GACancerCenter discuss this post hoc analysis by age and the importance of personalized treatment decisions > https://t.co/gziIsHQkam https://t.co/m31S47ama9